drugset / Trial / NCT03981094

A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants

NCT03981094

Phase 1 Completed 22 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with BMS-986278

Timeline

Start
2019-05-10
Primary completion
2019-07-27
Completion
2019-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Admilparant Small molecule Oral
Subject Pirfenidone Small molecule Oral